BGPT: Paper Review: Resistance to TRK inhibition mediated by convergent MAPK pathway activation

Fuel Your Discoveries

Quick Explanation Copied

Mechanism callout:

Off-target TRK-inhibitor resistance in GI TRK-fusion cancers frequently converges on MAPK pathway reactivation via acquired BRAF/KRAS/MEK alterations or upstream RTK (e.g., MET) signaling, and dual TRK + MEK blockade can restore pathway shutdown in relevant models.

Evidence drawn directly from the paper’s patient sequencing, cfDNA dynamics, orthogonal PDX/cell-line functional tests, and in vivo combination efficacy.

Long Explanation

Paper review (skeptical, evidence-first): 10.1038/s41591-019-0542-z

Title: Resistance to TRK inhibition mediated by convergent MAPK pathway activation
Date (from provided metadata): Aug 12, 2019 (published acceptance July 2, 2019 in paper header text)
Study type (as described in provided text): translational mechanism study combining prospective patient cfDNA/tumor sequencing + cell-line/PDX functional testing + in vivo combination efficacy.

Visual map: what the paper claims

In brief, resistance to TRK inhibitors is proposed to arise not only from on-target TRK kinase-domain mutations, but also from off-target bypass mechanisms that converge on MAPK pathway reactivation (either downstream—KRAS/BRAF/MEK—or upstream—e.g., MET amplification). The authors then test pathway-directed combinations (e.g., TRK + MEK; RAF+MEK for BRAF V600E; MET inhibition after MET amplification) and argue that upfront dual TRK + MEK may delay time-to-progression in GI TRK-fusion contexts.

Patient-level mechanistic evidence (as provided in the text)

Below is a compact reconstruction from the provided paper text + extracted research-data you supplied. (Important: this table does not include every mechanistic event ever mentioned in the full article—only those explicitly present in the text excerpt you provided.)

Patient / cancer	TRK inhibitor context	Acquired resistance alteration(s)	Key orthogonal evidence reported	Targeted countermeasure shown
Patient 1 — CTRC-NTRK1 pancreatic adenocarcinoma	Resistance to larotrectinib → later LOXO-195 (next-gen TRK inhibitor)	Acquired BRAF V600E (plus subclonal KRAS G12D in cfDNA)	Tumor biopsy + serial cfDNA + PDX outgrowth of a BRAF V600E–positive subclone; BRAF V600E ectopic expression conferred resistance to LOXO-195	RAF+MEK blockade dabrafenib + trametinib re-established regression / decreased mutant allele frequency (cfDNA)
Patient 2 — LMNA-NTRK1 CRC	Resistance to LOXO-195 after prior response to larotrectinib; had an on-target NTRK1 G595R at earlier stage	Emergence of multiple KRAS mutations (KRAS G12A/G12D reported)	Serial cfDNA dynamics; liver metastasis biopsy with KRAS G12A; later cfDNA showed KRAS G12D; KRAS-driven MAPK activation and resistance supported by ectopic expression	Paper reports upfront/combined strategies with MEK inhibition improving efficacy in preclinical models, but patient outcome on LOXO-195 + trametinib was not durable in the excerpt
Patient 3 — PLEKHA6-NTRK1 cholangiocarcinoma	Resistance to entrectinib → progressed on LOXO-195	Acquired MET high-level amplification (with MET protein overexpression)	MET amplification detected in sequencing; orthogonal confirmation by MET FISH and MET IHC; NTRK kinase domain did not show a point mutation in excerpt	LOXO-195 + crizotinib achieved marked shrinkage with disappearance of NTRK fusion and MET amplification in cfDNA (reported as transient)

Mechanistic network (Sankey): convergence onto MAPK

The paper’s narrative emphasizes convergence: multiple distinct acquired genomic events can ultimately yield MAPK output and bypass TRK dependency. The graph below encodes the directional logic stated in the excerpt: TRK inhibition pressure → acquired upstream RTK/downstream MAPK alterations → MAPK pathway activation → resistance.

Key experimental logic: correlation → causation (what’s strong, what’s uncertain)

Strengths (evidence that supports causality)

Prospective pairing of tumor biopsies and serial cfDNA to track resistance evolution—reduces the risk that the detected events are merely coincident.
Orthogonal confirmation for key events (e.g., MET amplification confirmed by FISH/IHC; BRAF V600E tracked in cfDNA and PDX outgrowth).
Ectopic expression sufficiency tests (e.g., KRAS/BRAF expression increasing MAPK activation and conferring resistance) support causality rather than mere association.

Limitations / blind spots (what could weaken the conclusion)

Small, heterogeneous patient subset (GI TRK-fusion resistance cases analyzed; in the provided excerpt: 8 total GI cases with serial cfDNA). Even if the mechanism is biologically plausible, generalizability to all TRK-fusion tumors and to non-GI contexts remains uncertain.
Convergence does not prove full sufficiency for every case: while multiple genomic events can activate MAPK signaling, other resistance layers may coexist (e.g., cell-state switching, parallel pathways, microenvironmental effects). The excerpt doesn’t provide a universal perturbation map across all bypass alterations.
Clinical responses reported as transient in some contexts (e.g., regressions achieved by targeted combinations ultimately transient). This suggests that even if MAPK reactivation is a key driver, further resistance trajectories can emerge.
Trial / inference risk: combination superiority in models does not automatically translate to durable benefit in patients, especially given differences in KRAS mutation identity and known resistance to MEK inhibition at clinically achievable exposures (as discussed in the excerpt).

Mechanism-to-therapy mapping (what was tried, and what it suggests)

From the excerpt: targeted countermeasures linked to bypass drivers

BRAF V600E / MAPK activation: RAF + MEK blockade (dabrafenib + trametinib) associated with tumor regression and reduced BRAF allele frequency in cfDNA in Patient 1 context.
MET high-level amplification: LOXO-195 + crizotinib yielded marked tumor shrinkage and disappearance of NTRK fusion and MET amplification in cfDNA, but with later reappearance of MET amplification and MET mutations in cfDNA.
KRAS-driven MAPK activation (downstream): combination logic emphasizes that MEK inhibition plus TRK inhibition can be required for dual pathway suppression in certain KRAS-mutant contexts, and upfront dual TRK+MEK may delay emergence of MAPK-bypass resistance.

Bottom line (confidence-tagged)

Most supported: The paper provides a coherent patient-to-mechanism linkage in a GI subset where acquired events repeatedly converge on MAPK pathway activation during TRK inhibitor resistance, and pathway-directed combinations can restore control in several contexts.

Moderate confidence: Upfront dual TRK+MEK may delay resistance emergence (delay vs prevent depends on baseline sensitivity/resistance state), but the excerpt also documents at least one clinical failure on LOXO-195 + trametinib, consistent with KRAS mutation–dependent insensitivity to MEK inhibition at achievable exposures.

What would disprove/limit the conclusion? A larger, multi-tumor randomized/stratified clinical dataset showing that MAPK-bypass mechanisms (as detected by their sequencing approach) reliably predict and are reliably overcome by TRK+MEK strategies; or mechanistic studies where MAPK reactivation is not sufficient to explain bypass phenotype in additional resistant tumors.

Conflict of interest (as provided in your text)

The excerpt includes multiple industry ties across authors (advisory boards/consulting/research funding and LOXO Oncology involvement). This does not negate mechanistic validity, but it increases the importance of scrutinizing how broadly the results are generalized and whether negative findings were omitted.

Suggested BGPT follow-ups (bespoke)

Author reviews (click-through)

Feedback:

Updated: April 25, 2026